

November 10, 2011  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer

**SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501)  
in Frontline Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma**

TOKYO, Japan, November 10, 2011 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, President & CEO: Fuminori Yoshida, "SymBio") announced that it initiated a phase 2 clinical trial on November 9 for bendamustine hydrochloride (SyB L-0501) in frontline low-grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL) patients in Japan. Patient enrollment in this multicenter open-label trial is underway.

In Japan, SymBio received marketing approval of TREAKISYM<sup>®</sup> (SyB L-0501) in October, 2010, for the treatment of patients with refractory/relapsed low-grade NHL and MCL. Working with Eisai Co. Ltd., TREAKISYM<sup>®</sup> is expected to achieve rapid market penetration in Japan.

The number of low-grade non-Hodgkin's lymphoma<sup>1</sup> patients in Japan is estimated to be around 11,000, including 4,000 refractory/relapsed patients and 7,000 untreated patients. Currently, R-CHOP<sup>2</sup> is prescribed as a standard therapy, however, clinical trial results in the U.S. and Europe have shown superiority of R-B<sup>3</sup> over R-CHOP in terms of safety and efficacy, leading to the inclusion of R-B in National Comprehensive Cancer Network (NCCN) guidelines<sup>4</sup> used by US physicians in prescribing oncology drugs.

SymBio has also initiated phase 2 trials for SyB L-0501 in refractory/relapsed intermediate and high-grade non-Hodgkin's lymphoma, and frontline multiple myeloma patients. The Company continues to pursue other indications for TREAKISYM<sup>®</sup> in the hematology space as nimbly as possible in order to maximize the potential of this 'pipeline within a molecule' and address other unmet medical needs in patients.

SymBio's financial forecast for FY 2011 will not be revised due to the acceptance of clinical trial notification.

**[Please read the following to learn more about Glossary, Bendamustine Hydrochloride (SyB L-0501), and SymBio Pharmaceuticals]**

[Contact]

Hiroki Maekawa

Board Director, Corporate Officer, Chief Financial Officer

Tel: +081(0)3 5472 1125

**Note to Editors**

**Glossary**

1 Non-Hodgkin's lymphoma: Lymphatic malignancy except for Hodgkin's lymphoma. In Japan, most of lymphomas is non-Hodgkin lymphoma. Non-Hodgkin's lymphoma is categorized by progression, which means lymphoma progressing annually is low-grade and monthly is mid and high grade.

2 R-CHOP: Combination therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone.

3 R-B: Combination therapy of Rituximab and Bendamustine

4 Network (NCCN) guidelines: An alliance of 21 of the world's leading cancer centers, these guidelines are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors.

**About Bendamustine Hydrochloride (SyB L-0501)**

Bendamustine was first synthesized in the early 1960s in former 'East Germany' by Jenapharm, and is currently marketed in Germany under the brand name "Ribomustin<sup>®</sup>" as a treatment for non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia. Mundipharma has received market authorization in a number of EU countries for bendamustine under the brand name "Levact<sup>®</sup>." In the United States, the drug has been approved by the U.S. Food and Drug Administration and is marketed as TREANDA<sup>®</sup> for the treatment of chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin's lymphoma. SymBio Pharmaceuticals Limited originally acquired the exclusive right from Astellas Deutschland GmbH (Headquarters: Munich, Germany, formerly Astellas Pharma GmbH) to develop and commercialize bendamustine in Japan (December, 2005), followed by signature of a second license agreement for the exclusive right to China/Hong Kong, Taiwan, South Korea and Singapore (March, 2007).

**About TREAKISYM<sup>®</sup>**

**Product Name:**

TREAKISYM<sup>®</sup> for Injection, for intravenous infusion 100 mg

**Generic Name:**

bendamustine hydrochloride

**Indications and Usage:**

For the treatment of relapsed or refractory forms of the following indications:

- Low-grade B-cell non-Hodgkin's lymphoma
- Mantle cell lymphoma

**Dosage and Administration:**

The standard adult dose of bendamustine hydrochloride is 120 mg/m<sup>2</sup> infused intravenously over 60 minutes on Days 1 and 2 of repeated 21-day cycles. The dose may be reduced as deemed appropriate according to the patient's condition.

**About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Ltd. was established in March, 2005 by Fuminori Yoshida, who previously served concurrently as Corporate VP of Amgen Ltd. and founding President of Amgen Japan (currently Takeda Bio Development Center Limited). The company's underlying corporate mission is "delivering hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs in the areas of oncology, hematology and autoimmune disease.